Skip to main content

Table 3 Top 10 adverse effects (3–4 grade) associated with pazopanib versus sunitinib

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Adverse effects

The number of study

Pazopanib group (event/total)

Sunitinib group (event/total)

RR (95% CI)

P value

Heterogeneity

I2 (%)

P value

Diarrhea

3

51/660

43/691

1.19 [0.81–1.74]

0.38

0

0.42

Fatigue

3

60/660

102/691

0.59 [0.44–0.80]

0.0006

0

0.49

Hypertension

2

83/626

93/648

0.43 [0.05–3.53]

0.43

78

0.03

Nausea/Vomiting

3

25/660

29/691

0.87 [0.52–1.46]

0.61

0

0.61

Leukopenia

2

6/626

39/648

0.26 [0.03–2.55]

0.25

84

0.01

Thrombocytopenia

2

20/626

131/648

0.16 [0.10–0.25]

< 0.00001

0

0.37

Neutropenia

2

28/626

127/648

0.23 [0.15–0.34]

<  0.00001

0

0.97

Increased creatinine

2

4/626

8/648

0.49 [0.15–1.63]

0.25

NA

NA

Increased AST

2

71/626

16/648

4.46 [2.62–7.58]

< 0.00001

0

0.69

Increased ALT

2

99/626

23/648

4.34 [2.79–6.75]

< 0.00001

0

0.40

  1. Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, NA: not available